New Stock News | Zhejing Pharmaceutical (688266.SH) plans to list in Hong Kong. The China Securities Regulatory Commission requires additional explanation of the specific implementation of overseas investment and other regulatory procedures.

The China Securities Regulatory Commission issued the "Requirements for Supplementary Materials for Overseas Issuance and Listing Registration (March 3, 2026 - March 13, 2026)". The CSRC International Department has issued supplementary material requirements for 8 companies, including a requirement for Zhejing Pharmaceutical (688266.SH) to provide further explanation on the specific implementation of overseas investment and foreign exchange registration regulatory procedures. According to the disclosure by the Hong Kong Stock Exchange on December 19, 2025, Zhejing Pharmaceutical has submitted an application to the main board of the Hong Kong Stock Exchange, with CICC as its exclusive sponsor. The CSRC has requested Zhejing Pharmaceutical to provide further explanation on the following matters, and to have lawyers verify and provide clear legal opinions: Please provide further explanation on the specific implementation of overseas investment, foreign exchange registration, and other regulatory procedures by your company's overseas subsidiaries, and provide a conclusive opinion on compliance. The prospectus shows that Zhejing Pharmaceutical is a comprehensive biopharmaceutical company, focusing on the discovery, research and commercialization of innovative small molecule and biologic therapy, with a strategic focus on oncology, autoimmune diseases, and hemostasis/blood diseases. Since its establishment in 2009, the company has established end-to-end capabilities covering drug discovery, research and development, production, and commercialization, thereby building a diversified and multi-level pipeline, and achieving successful commercialization.